Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
LOKELMA® (sodium zirconium cyclosilicate) is indicated for the treatment of hyperkalaemia in adult patients.
LOKELMA® (sodium zirconium cyclosilicate) is indicated for the treatment of hyperkalaemia in adult patients2
Down-titration or discontinuation of RAASi therapy in response to hyperkalemia can lead to 2x mortality risk1
Prescribing LOKELMA long-term results in lower rates of hyperkalaemia-related hospitalisations vs short-term therapy4
Guidelines state that RAASi down-titration should be last resort.5
Watch this video to learn about the mechanism of action of LOKELMA (sodium zirconium cyclosilicate)
Lokelma (sodium zirconium cyclosilicate) is developed and manufactured by AstraZeneca, a global, science-led biopharmaceutical company focused on the discovery, development, and commercialisation of prescription medicines, including treatments for cardiovascular, renal, and metabolic diseases.
LOKELMA received European Commission approval in 2018 for the treatment of hyperkalaemia in adult patients. It has since been approved and made available in multiple countries worldwide, including the UK.
Lokelma is a highly selective, non-absorbed potassium binder. It works by exchanging sodium and hydrogen ions for potassium in the gastrointestinal tract, helping to reduce elevated serum potassium levels (hyperkalaemia).
Yes. Lokelma can be used for both the correction and maintenance of normal serum potassium levels. Once potassium levels have been corrected, ongoing treatment can help maintain control of hyperkalaemia and enable patients to continue guideline-directed RAASi therapy for cardiorenal protection.
All Resources
LOKELMA dosing and administration card
Patient resource:
Guide to LOKELMA for hyperkalaemia
A quick guide that introduces your patients to LOKELMA and helps them to better understand hyperkalaemia
If you have any questions about LOKELMA or would like to speak to an
AstraZeneca representative, please contact us
CKD; chronic kidney disease; HF, heart failure; RAASi, renin-angiotensin-aldosterone system inhibitor.
GB-75599 | DOP: April 2026
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
GB-74216| DOP : February 2026
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
